use of arteriolar vasodilator in the management of advanced congestive heart failure

ABSTRACT

This study reports on therapeutic effect of hydralazine in the management of advanced congestive heart failure [ACHF] in Iraq. One hundred patients, with ACHF [class 4 of NYHA classification] were studied pressure, and the physical fitness for walking were taken as a follow up indicator for beneficial effect. Three months follow up after treatment showed that 50% of patients were stepped up to class 3 of NYHA. Six months follow up showed that 52% were in a good condition, and were satisfy the class 2 of NYHA. One year later 68% of the total patients were survived and they were stepped up, at least, one class of NYHA. Two years follow up showed that 60% of total patients were still surviving with 42% of them satisfy the criteria of class 2 of NYHA. The remaining patients of the total surviving [i.e. 18%] were in class 3 of NYHA. The mortality rate was 10%, 15% and 25% after 6 months, one year, and two years of treatment respectively. Incidence of sudden death was 5% among all patients through the 2 years period of study. As a result of the improvement in clinical states and reduction in mortality, hydralazine would be recommended to be used in the management of congestive heart failure